Healthcare Analysts Tewari and Taylor discuss Eli Lilly’s upcoming Ph.3 SURMOUNT-OSA (trial readout data expected Q124) and go over the impact GLP-1’s could have on OSA’s treatment paradigm on an Analyst/Industry conference call to be held on October 5 at 1:30 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- Jefferies healthcare analysts to hold an analyst/industry conference call
- Maxim starts Acrivon Therapeutics at Buy, sees ACR-368 as ‘just the beginning’
- ResMed price target lowered to $165 from $240 at Jefferies
- America’s food giants forced to confront Ozempic, weight loss drugs, WSJ says
- Novo Nordisk’s (NYSE:NVO) Ozempic Versus Snack Companies: The Debate Continues